Patient
SITE003-0008
completed Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE003 (CAN) (Dr. Okafor)
consented 2025-08-25
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 5
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-09-23 (study day 201); relationship: RELATED
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-07-18 (study day 134); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-04-29 (study day 54); relationship: NOT RELATED
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-03-30 (study day 24); relationship: not assessed
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-03-16 (study day 10); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.